Sprint Bioscience, together with Dr. Julian Walfridsson at Karolinska Institutet, is developing a methodology that can facilitate the identification of new unique drug targets for acute myeloid leukemia, AML. Dr. Walfridsson is a leading expert in the field and has developed advanced model systems to study the disease.
